Structure Therapeutics Inc.
NASDAQ:GPCRBiotechnology
+$0.39 today
- Market cap
- $999.36M
- Beta
- -1.42
- P/E (TTM)
- -19.3
- EPS (TTM)
- -$2.35
Volume 1.10M
Average 0.87M
GPCR Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Structure Therapeutics Inc.NASDAQ: GPCR
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $24.27M rose 223.3% year over year, ahead of the +103.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 108.5% from the prior quarter. Over 3 fiscal years it compounded at +125.9% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +223.3% holds above the trailing-twelve-month pace of +103.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 28.99M USD
- Year-over-year change
- +54.3%
- 4-year CAGR
- +110.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.99M | +54.3% |
| FY2024 | 2024-12-31 | 18.79M | +129.4% |
| FY2023 | 2023-12-31 | 8.19M | +225.8% |
| FY2022 | 2022-12-31 | 2.51M | +69.1% |
| FY2021 | 2021-12-31 | 1.49M | — |
Stock-Based Compensation vs competitors
How GPCR compares with its peers on the latest reported figures
- GPCR's LTM Jun 2026 stock-based compensation of $51.48M is the largest of the 8 companies compared; the peer median is $13M.
- Its year-over-year change of +103.6% is the 2nd highest of 7, against a peer median of +58.1%.
- Over three fiscal years its annual growth of +125.9% compares with a peer median of +66.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $51.48M | +103.6% | +125.9% | — | |
| LTM Jun 2026 | $25.03M | +73.0% | +248.9% | — | |
| LTM Mar 2026 | $20.28M | +92.0% | +34.5% | 101.4% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $19.67M | +177.6% | +77.3% | 20.4% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $13M | +43.2% | +66.3% | 126.0% |
KLRAKailera Therapeutics, Inc. | FY2025 | $10.94M | — | — | — |
| LTM Mar 2026 | $4.16M | -75.9% | -2.7% | — | |
| LTM Mar 2026 | $1.96M | -41.6% | — | 5.3% | |
| Peer median (excluding GPCR) | $13M | +58.1% | +66.3% | 60.9% | |
Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (38.05M) | (51.32M) | (89.62M) | (122.53M) | (141.2M) |
| Depreciation & Amortization | 72K | 277K | 295K | 992K | 1.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.49M | 2.51M | 8.19M | 18.79M | 28.99M |
| Change in Working Capital | 4.06M | 2.97M | 6.97M | 2.96M | (88.27M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.9M | 2.15M | (859.25K) | 3.31M | 4.77M |
| Other Working Capital | 2.17M | 815K | 7.83M | (343K) | (93.05M) |
| Other Non-Cash Items | 268K | (558K) | (5.32M) | (16.86M) | (23.05M) |
| Operating Cash Flow | (32.16M) | (46.12M) | (79.49M) | (116.64M) | (222.2M) |
| Capital Expenditures | (1.21M) | (155K) | (2.17M) | (1.29M) | (3.61M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (4.21M) | (123.45M) | (416.99M) | (702.52M) | (547.38M) |
| Sales of Investments | 23.28M | 61.5M | 151.05M | 344.9M | 630.54M |
| Other Investing Activities | 0 | 0 | (231.38K) | 0 | 10.25M |
| Investing Cash Flow | 17.86M | (62.11M) | (268.34M) | (358.91M) | 89.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 472.3M | 514.57M | 767.18M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (104K) | (2.49M) | (20.77M) | 690K | (4.66M) |
| Financing Cash Flow | 103.25M | 29.01M | 451.53M | 515.26M | 762.52M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (1.66M) |
| Net Change in Cash | 88.95M | (79.21M) | 103.7M | 39.72M | 630.12M |
| Free Cash Flow | (33.37M) | (46.28M) | (81.66M) | (117.93M) | (225.81M) |
Structure Therapeutics Inc.
NASDAQ:GPCR
Intrinsic Alpha fair value
Locked
Current Price
$17.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.